Fri, 12 Jun 2026
Headlines:
Anxiety over stalled clinical trial, says SAPP
Published on: Wednesday, May 18, 2022
Published on: Wed, May 18, 2022
Text Size:
Text:
Anxiety over stalled clinical trial, says SAPP
Kota Kinabalu: The Federal Health Ministry must engage in more effective communication and teamwork with Sabah medical team on the vaccine clinical trial programme protocol PRO-nCOV-3002, said Chin Vui Kai.

The SAPP Information Chief said children and adolescent participants after taking two shots, the programme was stalled for over three weeks without any information or communication from the health authorities of the next schedule or course of action.
Advertisement
Under the programme, children and adolescent participants were supposed to receive four injections of trial vaccine or placebo.

“The parents of these children who participated in the vaccine study programme, protocol named PRO-nCOV-3002, complained the health authorities of passing the buck and left them with a cloud of uncertainty over it,” he said.

SPONSORED CONTENT
Cosmobeauté Malaysia and beautyexpo will expand into East Malaysia with the launch of the Cosmobeauté Malaysia Borneo Festival 2026 at the Sabah International Convention Centre (SICC) from May 25 to 26.
“The programme was conducted at the Likas Women and Children’s Hospital. However, the medical personnel were not told or given directive by KL/Putrajaya on what should be done next. This further left the parents anxious and confused.

“We don’t want to wait until the
Advertisement
relevant authorities start finger-pointing for such incident. They should resolve the matter as soon as possible,” Chin opined.

According to Chin, feelings of uncertainty, anxiety, stress or even panic among the parents are listed as follows:
  1. The registration for the National Covid-19 Immunisation Programme for Children (PICKids) is ending soon.
  2. The interval between first and second vaccine dose has exceeded the recommended 2-4 weeks, if their child were given the real shot first and a placebo for the second injection.
  3. The immunity level of their child against Covid-19 virus is still unclear.

Advertisement
PRO-nCOV-3002 is a multi-centre, randomised, double-blind, placebo-controlled, Phase III Clinical Trial to evaluate the efficacy, immunogenicity and safety of Covid-19 vaccine in children and adolescents aged 3 to 17 years.

This study has been approved by the Medical Research and Ethics Committee under the Ministry of Health Malaysia. Healthy participants took part voluntarily in this study in Malaysia.
* Follow us on our official WhatsApp channel and Telegram for breaking news alerts and key updates!

* Do you have access to the Daily Express e-paper and online exclusive news? Check out subscription plans available.
Advertisement
Share this story
Advertisement
Advertisement
Follow Us  
           
Daily Express News  
© Copyright 2026 Sabah Publishing House Sdn. Bhd. (Co. No. 35782-P)
close
Try 1 month for RM 18.00
Already a subscriber? Login here
Try 1 month for RM 18.00
open
Try 1 month for RM 18.00
Already a subscriber? Login here